U.S. Advanced Therapy Medicinal Products Market Size & Outlook
U.S. advanced therapy medicinal products market, 2018-2030 (US$M)
Related Markets
U.S. advanced therapy medicinal products market highlights
- The U.S. advanced therapy medicinal products market generated a revenue of USD 2,969.9 million in 2023 and is expected to reach USD 0.0 million by 2030.
- The U.S. market is expected to grow at a CAGR of -100% from 2024 to 2030.
- In terms of segment, gene therapy was the largest revenue generating product in 2023.
Advanced therapy medicinal products market data book summary
| Market revenue in 2023 | USD 2,969.9 million |
| Market revenue in 2030 | USD 0.0 million |
| Growth rate | -100% (CAGR from 2023 to 2030) |
| Largest segment | Gene therapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, Cell Therapy, Tissue Engineered, Others (Combined ATMPs, for example biodegradable matric or scaffold) |
| Key market players worldwide | Bluebird bio Inc, Novartis AG ADR, UniQure NV, Gilead Sciences Inc, JCR Pharmaceuticals Co Ltd, Vericel Corp, Organogenesis Holdings Inc Class A, Spark Therapeutics, Celgene, Kolon Industries, Medipost, Pharmicell |
Other key industry trends
- In terms of revenue, U.S. accounted for 41.2% of the global advanced therapy medicinal products market in 2023.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Advanced Therapy Medicinal Products Market Scope
Advanced Therapy Medicinal Products Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. advanced therapy medicinal products market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to advanced therapy medicinal products market will help companies and investors design strategic landscapes.
Gene therapy was the largest segment with a revenue share of 52% in 2023. Horizon Databook has segmented the U.S. advanced therapy medicinal products market based on gene therapy, cell therapy, tissue engineered, others (combined atmps, for example biodegradable matric or scaffold) covering the revenue growth of each sub-segment from 2018 to 2030.
Substantial number of approved ATMPs for use in the U.S. has contributed to large revenue share held by the U.S. Recent approvals of products such as Kymriah and Yescarta have propelled investment in the U.S. ATMP market.
In May 2019, Zolgensma secured FDA approval for treatment of pediatric patients with SMA, exhibiting the constantly developing U.S. ATMP market. The FDA has announced that it has over 800 active Investigational New Drug applications on file by 2020 and the agency has shown interest to receive more than 200 applications per year.
Based on evaluation of current pipeline and their clinical success rates, Director of the Center for Biologics Evaluation and Research and the FDA Commissioner stated that the FDA would be approving around 10 to 20 cell & gene therapies per year.
Reasons to subscribe to U.S. advanced therapy medicinal products market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. advanced therapy medicinal products market databook
-
Our clientele includes a mix of advanced therapy medicinal products market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. advanced therapy medicinal products market , including forecasts for subscribers. This country databook contains high-level insights into U.S. advanced therapy medicinal products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. advanced therapy medicinal products market size, by product, 2018-2028 (US$M)
U.S. Advanced Therapy Medicinal Products Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
